ARS Pharmaceuticals公布2025年第四季度及全年财报,并更新Neffy®(肾上腺素鼻喷雾剂)商业化进展

美股速递
Mar 09

ARS Pharmaceuticals Inc(纳斯达克代码:SPRY)近日披露了2025年第四季度及全年的财务业绩,同时就旗下创新产品Neffy®(肾上腺素鼻喷雾剂)的商业化进程提供了最新动态。报告显示,公司在关键财务指标上达成预期目标,并为鼻喷雾剂的上市筹备工作制定了明确时间表。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10